These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 14639671)

  • 41. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
    Huot P; Johnston TH; Lewis KD; Koprich JB; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
    Neuropharmacology; 2014 Jul; 82():76-87. PubMed ID: 24447715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 5-HT
    Kwan C; Frouni I; Bédard D; Nuara SG; Gourdon JC; Hamadjida A; Huot P
    Exp Brain Res; 2019 Feb; 237(2):435-442. PubMed ID: 30443669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Visanji NP; Gomez-Ramirez J; Johnston TH; Pires D; Voon V; Brotchie JM; Fox SH
    Mov Disord; 2006 Nov; 21(11):1879-91. PubMed ID: 16960862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
    Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Experimental Models of l-DOPA-Induced Dyskinesia.
    Johnston TH; Lane EL
    Int Rev Neurobiol; 2011; 98():55-93. PubMed ID: 21907083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
    Frouni I; Belliveau S; Maddaford S; Nuara SG; Gourdon JC; Huot P
    Eur J Pharmacol; 2021 Nov; 910():174452. PubMed ID: 34480885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
    Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P
    Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata.
    Yamamoto N; Pierce RC; Soghomonian JJ
    Brain Res; 2006 Dec; 1123(1):196-200. PubMed ID: 17027936
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Tomiyama M; Kimura T; Maeda T; Kannari K; Matsunaga M; Baba M
    Neurosci Res; 2005 Jun; 52(2):185-94. PubMed ID: 15893579
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of the mGlu
    Frouni I; Kwan C; Bédard D; Kang W; Hamadjida A; Nuara SG; Gourdon JC; Huot P
    Psychopharmacology (Berl); 2023 Oct; 240(10):2093-2099. PubMed ID: 37516708
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
    Bishop C; Taylor JL; Kuhn DM; Eskow KL; Park JY; Walker PD
    Eur J Neurosci; 2006 May; 23(10):2669-76. PubMed ID: 16817869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.
    Huot P; Johnston TH; Koprich JB; Winkelmolen L; Fox SH; Brotchie JM
    Neurobiol Aging; 2012 Jan; 33(1):207.e9-19. PubMed ID: 21051107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
    Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.